A shift in how IoT is secured by default

Tern plc

The release of KeyScaler 2025 marks a transformational moment for organisations wrestling with sprawling IoT and OT device estates. Rather than accepting the traditional burden of manual certificate issuance, policy definition and certificate revocation across thousands or even millions of devices, KeyScaler 2025 introduces a fully automated, AI‑driven trust lifecycle.

Manual processes have long been the Achilles’ heel of large‑scale deployments, introducing delays, human error and security gaps. By embedding AI that continuously monitors device behaviour, identity attributes and compliance posture, KeyScaler 2025 is designed to detect anomalies and potential threats in real time, and to trigger remediation automatically.

The platform incorporates a ‘Policy Intelligence Engine’ that enforces zero‑trust principles dynamically, adapts permissions based on contextual threat data and ensures data exchanges remain encrypted and auditable. For industries such as manufacturing, healthcare, energy or logistics, these features offer critical assurances.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Talking Medicines targets better pharmaceutical launch results through message analysis

Talking Medicines' Message Resonance Score measures doctors' understanding of pharmaceutical messaging to help companies improve launch strategies.

Device Authority addresses security risks as AI takes control of physical machines

Device Authority's KeyScaler platform supports secure AI-driven automation by helping organisations authenticate connected machines, protect device identities and control access to physical equipment.

Talking Medicines examines factors influencing prescribing decisions

Talking Medicines explains how healthcare professional conversations, clinical considerations and treatment perceptions can provide pharmaceutical companies with deeper insight into prescribing intent beyond traditional campaign metrics.

What HCPs say could reveal prescribing intent

Talking Medicines is using AI to analyse HCP conversations and identify the clinical and practical factors that may influence prescribing intent.

AI control of machines raises new security questions

AI is gaining the ability to control physical equipment, but establishing that machines are genuine, authorised and secure will be an important part of making this technology safe to deploy.

CAR-T therapy brings new approach to multiple myeloma treatment

CAR-T therapy is being used in multiple myeloma and is being studied earlier in the treatment pathway, with research focused on improving durability, safety and access.

Search